Maze Therapeutics vs Protalix BioTherapeutics
MAZE and PLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MAZE and PLX compare
Maze Therapeutics is the larger company, worth 8.1 times as much as Protalix BioTherapeutics ($2.0B against $252M).
Protalix BioTherapeutics scores higher on the StockData Score (16 against 4 for Maze Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MAZE | PLX |
|---|---|---|
| Size and price | ||
| Market cap | $2.0B | $252M |
| Share price | $36.73 | $3.13 |
| Change, 1 year | 20.5% | 46.9% |
| Change, 5 years | – | 219% |
| Beta (5Y) | 0.90 | 0.87 |
| Employees | 141 | 226 |
| StockData Score | ||
| Total score | 4 | 16 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 1 | 4 (better) |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 12.5× |
| P/S | – | 3.0× |
| P/B | 4.8× | 3.1× (better) |
| EV/EBITDA | – | 9.1× |
| P/FCF | – | 16.7× |
| FCF yield | −5.6% | 6.0% (better) |
| Fair value | – | $6.08 |
| Margin of safety | – | 48.5% |
| Growth | ||
| Revenue growth (TTM) | – | 37.0% |
| Revenue growth, 5Y average | – | −3.5% |
| Net income growth (TTM) | – | 281% |
| EPS growth (TTM) | – | 525% |
| Profitability | ||
| Gross margin | – | 71.2% |
| Operating margin | – | 29.8% |
| Net margin | – | 24.3% |
| FCF margin | – | 17.8% |
| Return on equity | −37.5% | 30.8% (better) |
| Return on invested capital | −353% | 41.0% (better) |
| Financial health | ||
| Debt / equity | 0.09 (better) | 0.00 |
| Current ratio | 14.14 (better) | 3.27 |
| Altman Z-score | 12.90 (better) | 6.13 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 105% | 17.9% |
| Held by insiders | 16.9% | 3.8% |
| Insider net buying, 12 months | −$25.0M | $101K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 14.5% | 4.5% |
Go deeper
- MAZE stock overview
- MAZE income statement
- MAZE valuation and score
- PLX stock overview
- PLX income statement
- PLX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.